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Abstract
The association of primary sclerosing cholangitis (PSC) 
and autoimmune hepatitis (AIH) is known as an over-
lap syndrome (OS). OS can also be described in the 
setting of concomitant presence of AIH and PSC. These 
diseases can in some cases be associated with ulcer-
ative colitis. In this case report we describe, to our 
knowledge, the first case in the literature of a young 
Caucasian male suffering from ulcerative colitis and an 
overlap syndrome consisting of an association between 
PSC-AIH, with the concomitant presence of a membra-
nous glomerulonephritis.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: This case reports highlights a particular kind 
of hepatic overlap syndrome. To our knowledge it 
would be the first case to be described in the literature 
concerning 4 different diagnoses; all being autoim-
mune related. These autoimmune diseases were never 
described together, yet their association in this case is 
probably not a sheer coincidence. Auto-immune diseas-
es will play an ever more import role in the future; yet 
the current knowledge and understanding concerning 
these pathologies is certainly only a fraction of what is 
necessary to offer the best treatment to our patients.
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INTRODUCTION
The term “primary sclerosing cholangitis-autoimmune 
hepatitis (PSC-AIH) overlap syndrome” is used to de-
scribe different varieties of  AIH and/or PSC in the set-
ting where an unspecific number of  characteristics of  the 
other disease are present[1].
Herein we report a particular kind of  hepatic overlap 
CASE REPORT
syndrome. To our knowledge it would be the first case to 
be described in the literature concerning a patient with 
ulcerative colitis, PSC, auto-immune hepatitis, and extra-
membranous glomerulonephritis. These autoimmune dis-
eases were never described together, yet their association 
in this case is probably not a sheer coincidence. 
CASE REPORT
We report the case of  a 29-year-old Caucasian male suf-
fering from ulcerative colitis (UC) since 2000 and associ-
ated with PSC since 2003. The initial diagnosis of  UC 
was based on concordant endoscopic and histological 
findings, and PSC diagnosis was established by means of  
a liver biopsy. The patient was treated using 1 g/d of  ur-
sodeoxycholic acid. 
In September 2005, the patient was hospitalized for 
jaundice and fatigue without any indication of  pain. Be-
sides a lean physique and conjunctival jaundice, the clini-
cal examination was inconspicuous. 
Initial blood analysis showed impaired liver function 
characterized essentially by the presence of  cholestasis 
and cytolysis (Table 1). Further investigation showed 
increased IgG [25.2 (normal: 6.9-14) g/L) and IgM 
[2.36 (normal: 0.3-2.1) g/L] titers. Subanalysis for IgG4 
and anti-nuclear antibodies remained negative. Anti-
mitochondrial antibodies type 2, anti-myeloperoxidase, 
as well as anti-LKM were also negative. However, anti-
neutrophil cytoplasmic antibodies (determined by indi-
rect immunofluorescence assay) and anti-proteinase 3 
antibodies turned out to be positive. Serotype analysis 
confirmed the presence of  HLA-DR 3 in our patient. 
Further analyses concerning tumor markers (alpha feto-
protein, carcinoembryonic antigen, and CA19-9) as well 
as hepatitis serology (A, B, and C) were negative. Urinary 
copper levels were normal and no Keiser Fleischer rings 
were noted at clinical examination. Abdominal ultrasound 
only demonstrated the presence of  dilated intrahepatic 
bile ducts. This picture was confirmed by endoscopic 
retrograde cholangiopancreatography (ERCP), which 
showed some minor irregularities of  the intrahepatic 
portion. Cholangio-magnetic resonance imaging (MRI) 
proved to be non-contributive and only confirmed the 
results obtained by the ERCP. The overall appearance 
was compatible, but not specific for sclerosing cholangi-
tis. A liver biopsy performed shortly afterwards showed 
the presence of  chronic hepatitis with predominantly 
centrilobular necrosis (Figure 1), evoking a toxic origin 
or possibly AIH. Owing to the increased IgGs with con-
comitant cytolysis and the exclusion of  any other causes 
(i.e., toxics) the diagnosis of  AIH associated with PSC 
was retained, delimitating the picture of  an overlap syn-
drome. The patient was promptly started on 32 mg/d of  
methyl-prednisolone. Seven days after the initiation of  
the treatment, there was a marked improvement in the 
patient’s overall condition. Total bilirubin dropped to 53 
mg/L. Alanine aminotransferase and IgGs were signifi-
cantly decreased to 228 U/L and 15.4 g/L, respectively. 
However, the IgGs titers fluctuated for the next four 
years before reaching a normal level again. Two months 
later, corticosteroids were reduced by half  (16 mg/d). 
Nonetheless we were forced to start the patient on 50 
mg/d of  azathioprine shortly after this step, as liver func-
tion degraded. This medication was so poorly tolerated 
by the patient that he was switched to 6-mercaptopurine 
(6-MP). The dosage was steadily increased to 75 mg/d. 
TPMT gene variant genotyping didn’t show any abnormal 
activity, therefore excluding a genetic predisposition to 
bone marrow toxicity. Further withdrawal of  corticoste-
roids proved to be difficult as clinical jaundice reoccurred 
as soon as the dosage was reduced 8 mg/d or less. As 
liver function [total bilirubin: 61 mg/L (range < 4 mg/L), 
TGP 72 UI/L (range: 3-36 UI/L)] as well as clinical evo-
lution of  the patient stagnated, we temporarily interrupt-
ed the administration of  ursodeoxycholic acid to exclude 
any possible drug interaction. The titers for 6-MP were in 
normal range and another cholangio-MRI proved to be 
non-contributive. We therefore suspected a new episode 
of  AIH, which led us to increase corticosteroids to 12 
mg/d. This decision promoted into an excellent clinical 
and biological evolution with almost a complete normal-
ization of  liver function. Following this good evolution, 
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Table 1  Initial biology at first presentation
Value Range
Hemoglobin (g/dL) 12.1 14.0-17.4 
Gamma glutamyltransferase (UI/L) 157 8-61 
C-reactive protein (mg/dL)      11.5 < 10 
GOT (AST, UI/L) 920 0-35 
TGP (ALT, UI/L) 701 3-36 
Total bilirubin (mg/dL)    123.7 < 15
Direct bilirubin (mg/dL)      93.8 < 4 
Amylase (UI/L)   94 < 160 
Lipase (UI/L)   77 < 140 
Alkaline phosphatase (UI/L) 208   35-100 
Total low density lipoprotein (UI/L) 429   95-195 
Albumin (g/dL)      33.4 35-50 
ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GOT: 
Glutamate oxaloacetate transaminase; TGP: Glutamate pyruvate transami-
nase. 
50 mm
Figure 1  Hematoxylin eosin. Centrilobular necrosis (disorganized appear-
ance) (red arrow) centrilobular vein (black arrow) (original magnification × 40). 
corticosteroids were decreased progressively to 8 mg/d, 
which would be the minimum dose required for the next 
several years.
In October 2009, four years after the initial diagnosis 
of  overlap syndrome, the patient presented himself  to 
the emergency department with severe edema of  the 
lower extremities.
Besides a raised blood pressure of  155/105 mmHg, 
clinical examination was unremarkable. At that moment 
the patient treatment consisted of  75 mg/d of  6-mer-
captopurine, 8 mg/d of  methyl-prednisolone, 1 g/d of  
ursodeoxycholic acid, and 2 g/d of  mesalazine. Blood 
work performed at the emergency department showed 
hypoalbuminemia [17 (range: 35-50) g/L] with normal 
creatinine level [1.15 (range: 0.6-1.3) mg/dL]. A 24 h 
urine sample confirmed the presence of  severe nephrotic 
syndrome with a proteinuria of  23400 mg/L, or 10400 
mg/g of  creatinine with a total of  46.3% of  albumin. 
The protein fractions were normal. An abdominal ul-
trasound was unremarkable. On the next day kidney 
biopsies (Figures 2 and 3) were performed showing the 
presence of  an extra-membranous glomerulonephritis. 
Immunohistology showed the presence of subepithelial 
deposits of  IgG, C3d, and C4d. C1q, IgA, and IgMs were 
not detected. Despite the absence of  renal failure, the 
presence of  massive proteinuria pushed us to increase the 
corticosteroids to 64 mg/d. Cyclophosphamide, as well 
as calcineurin inhibitors, were not available as alternatives 
due to the patient receiving 6-MP at that time. This treat-
ment was supplemented with bumetanide 0.5-1 mg/d, 
lisinopril 20 mg/d, CaCO3 1250 mg/d, and omeprazole 
20 mg/d. One month after initiation of  treatment, the 
nephrotic syndrome went into complete remission. Di-
uretics were stopped and corticosteroids were progres-
sively reduced. Unfortunately, the nephrotic syndrome 
reemerged as soon as corticosteroids were weaned, and 
after two consecutive episodes we decided to convert the 
treatment regimen to cyclophosphamide 2 mg/kg per 
day. 6-MP was stopped during the next 6 mo. The patient 
responded well to this alteration so that corticosteroids 
could again be reduced to 16 mg/d. Liver function re-
mained stable.
In August 2011, the clinical and biological evolution 
stabilized so that the patient was finally weaned from 
systemic corticosteroids. His final treatment consisted 
of  5 mg/d of  beclomethasone, 75 mg/d of  6-MP, 2 g/d 
of  mesalazine, and 1 g/d of  ursodeoxycholic acid. The 
administration of  cyclophosphamide was stopped indefi-
nitely.
DISCUSSION
The term “PSC-AIH overlap syndrome” is used to de-
scribe different varieties of  AIH autoimmune and/or 
PSC in a setting where an unspecific number of  charac-
teristics of  one disease are present[1].
Other forms of  overlap syndromes have been de-
scribed as combining the simultaneous presence of  dif-
ferent diseases like AIH and primary biliary cirrhosis. A 
precise clinical and pathological definition is still missing. 
Concerning PSC-AIH overlap syndrome, Czaja[2] sug-
gested that it is possibly an atypical manifestation of  a 
classic disease, rather than a completely new entity. How-
ever, the International Auto-Immune Hepatitis Group 
(IAIHG) takes no clear position on the matter, leaving 
the door open to a wide variety of  possibilities: consecu-
tive presentation, concomitant presentation, existence of  
a continuum between the two diseases, or presence of  a 
disease that also has one or more other features of  the 
other[3]. The PSC-AIH overlap syndrome is most often 
described in children, adolescents, or young adults[1,3-5]. 
Before confirming the diagnosis of  an overlap syndrome 
it is of  the upmost importance to exclude liver toxicity of  
the pre-existing treatment.
Most large series published in the literature[5-7] con-
cerning overlap syndrome present patients with an initial 
diagnosis of  PSC to whom the diagnostic criteria for 
auto-immune hepatitis were applied to diagnose or postu-
late the presence of  an overlap syndrome. This situation 
is comprehensible in the light that well-defined inclusion 
criteria, although needed, are still absent. The IAIHG 
recalls, however, that clear and strict criteria are not in-
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Figure 2  Optic microscopy: Jones’ staining. Presence of spikes in a diffuse 
manner (arrows) (silver impregnation of the basement membrane, original mag-
nification × 400). 
Figure 3  Immunoperoxidase (anti-IgG Ab). Binding of the antibody in the 
sub-epithelial region of the basal membrane. The immunofixation for C3d and 
C4d are positive in the same locations, original magnification × 400.
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disease, and that the impact of  ursodeoxycholic acid may 
be different if  used much earlier. However, this statement 
has not been fully evaluated[4]. The notion of  overlap syn-
drome is important because it has been shown[2] that in 
cases of  PSC-AIH overlap there is a weakened response 
to corticosteroids. It has been equally shown[2,3] that 
patients, like the one presented in this case report, with 
AIH, PSC, and ulcerative colitis, have a reduced probabil-
ity of  remission and higher treatment failure rates than 
patients with normal cholangiography. 
The IAIHG noted several working groups that men-
tion a benefit of  steroids, but also mentions another 
group who found a reduced response in these particular 
patients[8]. Several reviews[4,14] also suggest that liver trans-
plantation is indicated for advanced stages of  this disease.
Extra-intestinal manifestations of  inflammatory bow-
el disease, like glomerulonephritis (GN), are considered 
rare[15] in cases of  overlap syndrome. In such instances, 
GN can have a wide spectrum from minimal change to 
rapidly progressive (crescent) GN, and may also be ac-
companied by active tubular-interstitial nephritis[15]. 
However, we only found 6 cases of  membranous glo-
merulonephritis associated with ulcerative colitis[16-21] and 
only one published case of  PSC associated with membra-
nous glomerulonephritis by Verresen et al[22] in 1988. Fur-
thermore, there are 3 described cases in which an extra-
membranous glomerulonephritis is associated with auto-
immune hepatitis[23-25].
Lastly, in our review of  the literature we found one 
case similar to the one mentioned in here (i.e., suffering 
from UC alongside with PSC and membranous glomeru-
lonephritis)[26]. To our knowledge, this case report seems 
to be the only one presenting a patient with UC, an over-
lap syndrome involving PSC and AIH, and membranous 
glomerulonephritis.
Glomerulonephritis caused by aminosalicylates, cyclo-
sporine[15,27-29], and tumor necrosis factor-α inhibitor[27,28] 
are well known, and described even with a delayed pre-
sentation after several years of  continuous treatment[30]. 
6-mercaptopurine shows no significant direct nephro-
toxicity[28]. In the group of  six patients described with 
membranous glomerulonephritis associated with ulcer-
ative colitis, 4 patients[17,18,20,21] did not receive potentially 
nephrotoxic treatment before the onset of  nephrotic 
syndrome. So it seems that the treatment may not be in-
criminated in the association of  these diseases blindly.
Currently, the research concerning the pathophysiol-
ogy of  glomerulonephritis is in full progress. The recent 
discovery of  the phospholipase A2 receptor as a target 
antigen in 70% of  membranous glomerulonephritis[31] 
validates these efforts. Nonetheless, until now no study 
has been able to link certain forms of  membranous glo-
merulonephritis and ulcerative colitis, even though the 
autoimmune context seems inevitable.
COMMENTS
Case characteristics
Jaundice, fatigue, and edema in a patient with ulcerative colitis and primary 
tended to diagnose an overlap syndrome[3].
A study published in 2005[5] estimated that 17% of  
patients with PSC have an overlap syndrome (PSC + 
AIH according to the criteria of  IAIHG 1999[8]). On 
behalf  of  the IAIHG[8], Boberg estimated a prevalence 
of  1.8% of  AIH (according to the diagnostic criteria of  
the IAIHG) and 8.8% of  probable AIH (according to 
the criteria of  the IAIHG) in a sample of  114 patients 
suffering from PSC. If  one would consider that the diag-
nosis of  overlap syndrome doesn’t necessitate a complete 
coverage of  both diagnostic criteria of  each disease, these 
figures would be much higher.
The patient mentioned in this case report meets both 
diagnostic criteria for PSC[9,10], as well as for AIH, accord-
ing to the IAIHG criteria[8], giving us the confidence to 
diagnose our patient with overlap syndrome. It is impor-
tant to note that centrilobular necrosis has been described 
in cases of  AIH, particularly in young patients as well as 
in hepatic transplants[11,12]. No antibody were detected in 
our patient, but this is the case in almost 10% of  AIH[3].
A prospective study[5] of  41 patients comparing those 
with PSC (n = 37) alone vs those associated with autoim-
mune hepatitis (n = 7) showed that patients in the lat-
ter group were generally younger, had higher IgGs, and 
higher levels of  transaminases. The authors believe that 
there is a benefit of  treating such patients with immu-
nosuppressive and ursodeoxycholic acid. Patients with 
overlap seemed to have a better survival than those with 
PSC alone[5]. However, this study didn’t take into account 
the possibility that the difference in survival may be due 
to the fact that patients in the overlap group generally 
presented with less severe forms of  PSC. These findings 
are nonetheless in sharp disagreement with the fact that 
patients with overlap syndrome have a lower response 
rate than those with PSC. Statistical analysis methods are 
not detailed in this study, therefore rendering correct in-
terpretation of  results difficult.
Given the lack of  specific diagnostic criteria, it is dif-
ficult to establish a line of  scientifically proven conduct. 
The guidelines published by the European Association 
for the Study of  the Liver (EASL) recommend treating 
patients with AIH-PSC overlap by ursodeoxycholic acid 
and immunosuppressive agents, even though this is not 
“evidence-based” per se[9]. Note that the American Asso-
ciation for the Study of  Liver Diseases also recommends 
the use of  corticosteroids and immunosuppressive agents 
in these patients[3]. This is in agreement with the usual 
treatment of  patients with PSC associated with ulcerative 
colitis, since it appears that the treatment of  PSC with 
ursodeoxycholic acid reduces not only the risk of  dyspla-
sia[4], but also the prevalence of  colorectal carcinomas[4,13], 
and should be given to every patient with ulcerative colitis 
and PSC. However, the EASL puts forward that no study 
could demonstrate any positive effects on the prognosis 
of  patients with PSC, and that the treatment is therefore 
not “evidence-based”[9]. Culver and Chapman published a 
review in 2011[4] on the management of  the treatment of  
sclerosing cholangitis and its variants, and concluded that 
many studies included patients with advanced stages of  
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sclerosing cholangitis. 
Clinical diagnosis
Overlap syndrome [autoimmune hepatitis (AIH) and primary sclerosing chol-
angitis (PSC)] and membranous glomerulonephritis in a patient with ulcerative 
colitis. 
Differential diagnosis
PSC exacerbation, primary biliary cirrhosis, Wilson disease, and neoplasia are 
all valid differential diagnoses for hepatic alteration should nephritic syndrome 
due to treatment toxicity be excluded.
Laboratory diagnosis
Elevation of liver enzymes and IgG for the diagnosis of AIH. Proteinuria and 
hypoproteinemia for the membranous nephritis.
Imaging diagnosis
For the liver, magnetic resonance imaging and computer tomography were not 
contributive; the diagnosis is based on histological findings. Such methods are 
nonetheless necessary to exclude other causes (i.e., neoplastic). For the kid-
ney, the diagnosis is made by means of a urine analysis and kidney biopsy.
Pathological diagnosis
Ulcerative colitis was diagnosed by endoscopy and histology, primary scleros-
ing cholangitis by magnetic resonance imaging and histology, auto-immune 
hepatitis by histology, and the criteria of the International Auto-Immune Hepatitis 
Group. Extra-membranous glomerulonephritis was diagnosed by histology (with 
Jones’ staining).
Treatment
Corticosteroids are used in treatment in cases of auto-immune exacerbation. 
Maintenance treatment could be azathioprine, ursodeoxycholic acid for auto-
immune hepatitis and primary sclerosing cholangitis, or cyclophosphamide for 
the treatment of membranous nephritis.
Term explanation 
The term “PSC-AIH overlap syndrome” is used to describe different varieties 
of autoimmune hepatitis autoimmune and/or primary sclerosing cholangitis in a 
setting where an unspecific number of characteristics of the other disease are 
present. The term overlap just designs an association of disease. It’s not very 
clear if it’s just a concomitant presence of the disease, the potential, or if the 
overlap design are a variant of the diseases. 
Experiences and lessons
It’s very important not to forget that clear diagnostic criteria are sometimes more 
of a theoretical concept and rarely apply to the circumstances found in a spe-
cific patient. Therefore a correct knowledge and interpretation of the different 
sub-characteristics of each disease is the key to allowing tailored therapeutic 
approaches.
Peer review
This paper reports associated “autoimmune” diseases in a single patient. The 
addition of membranous glomerulonephritis to ulcerative colitis and a PSC-AIH 
overlap is new information. A short note on this new association could be of 
interest and useful for the future.
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